Acadia Pharmaceuticals Inc (NASDAQ: ACAD) is -36.19% lower on its value in year-to-date trading and has touched a low of $17.71 and a high of $33.99 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The ACAD stock was last observed hovering at around $24.13 in the last trading session, with the day’s loss setting it -4.15%.
Currently trading at $19.98, the stock is -18.88% and -25.03% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 7.4 million and changing -17.20% at the moment leaves the stock -21.91% off its SMA200. ACAD registered -1.91% loss for a year compared to 6-month loss of -26.35%. The firm has a 50-day simple moving average (SMA 50) of $4.01 and a 200-day simple moving average (SMA200) of -$42.91.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -24.20% gain in the last 1 month and extending the period to 3 months gives it a -4.77%, and is -16.09% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.83% over the week and 4.29% over the month.
Acadia Pharmaceuticals Inc (ACAD) has around 598 employees, a market worth around $3.29B and $726.44M in sales. Fwd P/E is 14.93. Profit margin for the company is -8.44%. Distance from 52-week low is 12.82% and -41.22% from its 52-week high. The company has generated returns on investments over the last 12 months (-12.78%).
Acadia Pharmaceuticals Inc quarterly earnings per share for the current quarter are estimated at $0.06 with sales reaching $208.91M over the same period.The EPS is expected to grow by 279.58% this year, but quarterly earnings will post 33.00% year-over-year. Quarterly sales are estimated to grow 76.40% in year-over-year returns.
Acadia Pharmaceuticals Inc (ACAD) Top Institutional Holders
382 institutions hold shares in Acadia Pharmaceuticals Inc (ACAD), with institutional investors hold 99.85% of the company’s shares. The shares outstanding are 164.65M, and float is at 163.51M with Short Float at 6.61%. Institutions hold 99.40% of the Float.
The top institutional shareholder in the company is Baker Brothers Advisors, LLC with over 42.86 million shares valued at $1.03 billion. The investor’s holdings represent 26.18% of the ACAD Shares outstanding. As of Jun 29, 2023, the second largest holder is Vanguard Group Inc with 13.85 million shares valued at $331.82 million to account for 8.46% of the shares outstanding. The other top investors are Blackrock Inc. which holds 10.04 million shares representing 6.13% and valued at over $240.45 million, while RTW Investments LP holds 5.98% of the shares totaling 9.78 million with a market value of $234.31 million.
Acadia Pharmaceuticals Inc (ACAD) Insider Activity
The most recent transaction is an insider sale by DAVIS STEPHEN,the company’sCEO. SEC filings show that DAVIS STEPHEN sold 5,577 shares of the company’s common stock on Feb 26 ’24 at a price of $24.67 per share for a total of $0.14 million. Following the sale, the insider now owns 0.1 million shares.
Acadia Pharmaceuticals Inc disclosed in a document filed with the SEC on Feb 26 ’24 that Schneyer Mark C. (EVP, CHIEF FINANCIAL OFFICER) sold a total of 772 shares of the company’s common stock. The trade occurred on Feb 26 ’24 and was made at $24.67 per share for $19045.0. Following the transaction, the insider now directly holds 21067.0 shares of the ACAD stock.
Still, SEC filings show that on Feb 26 ’24, Teehan Brendan (EVP, COO, HEAD OF COMMERCIAL) disposed off 624 shares at an average price of $24.67 for $15394.0. The insider now directly holds 31,432 shares of Acadia Pharmaceuticals Inc (ACAD).
